(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Summit Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast SMMT's revenue for 2026 to be $42,888,697,991, with the lowest SMMT revenue forecast at $42,888,697,991, and the highest SMMT revenue forecast at $42,888,697,991. On average, 2 Wall Street analysts forecast SMMT's revenue for 2027 to be $91,612,442,440, with the lowest SMMT revenue forecast at $19,991,119,978, and the highest SMMT revenue forecast at $163,233,764,901.
In 2028, SMMT is forecast to generate $1,150,961,069,767 in revenue, with the lowest revenue forecast at $747,048,236,241 and the highest revenue forecast at $1,554,873,903,294.